Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Drugs, At What Cost?

January 15, 2014

As austerity, the patent cliff, and regulatory practices continue to shape the financial outlook for pharma, the key question is: What price can (or will) patients pay for the therapy?

The 7 Habits of Highly Effective Competitors

January 13, 2014

Biopharma's best companies provide valuable lessons for preparing, planning, and playing to win. Stan Bernard shows us how.

Checking the Box on Early Commercialization

January 10, 2014

Failure to improve successful launch rates will doom your company to marginalization in the fight for brand affinity — not to mention the prescriber loyalty that keeps medicines in play for the long haul.

The iPad's Future in Pharma

January 8, 2014

Three years into the Apple-led tablet era, the iPad is still being used as no more than a glorified touchscreen. Gabriel Cangiano, Ron Kane, and David Windhausen look at the key role it can play in the future of pharma.

US Pharma Challenges 2014

January 8, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.

Tracking Innovation in 2013's New Molecular Entities

January 6, 2014

Patricia Van Arnhum reviews 2013's crop of the new molecular entities and new biologics license applications approved by FDA.

The Climate Change in Outsourcing

January 2, 2014

Financial, political, and scientific developments that began 10 years ago are only now being felt by the biopharmaceutical contract services industry, writes Jim Miller.

Biotechnology Innovation and Growth in Israel

December 16, 2013

Israel's diverse population, high-quality healthcare system, and resilience to global financial stress make it a strong partner for R&D, clinical research, and market growth.

Develop Drugs for People, Not Just Bodies

December 1, 2013

A patient-centric approach to drug development delivers the benefits that actually create value, writes Charlotte Vansgaard and Mikkel Brok-Kristensen.

ADVERTISEMENT

Click here